Norcliffe Capital

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.

Glen Clova Scientific is focused on developing a new generation of active biological drugs that aim to create natural antibodies against harmful targets. These innovative drugs are designed to improve the treatment of chronic diseases by minimizing the need for safety monitoring and reducing the frequency of dosing. As a result, patients benefit from a more cost-effective treatment approach, while the company also seeks to address healthcare challenges in markets with limited infrastructure.

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Aureum Diagnostics is a point of care diagnostics platform and medical equipment manufacturer focused on developing innovative tools for diagnosing various life-threatening conditions, including COVID-19. The company utilizes an electrochemical sensor combined with a handheld, low-cost instrument to deliver rapid and highly sensitive measurements of multiple biologically significant targets. By integrating proprietary sensors, reagents, and instrumentation innovations, Aureum Diagnostics aims to enhance clinical decision-making and improve patient outcomes through timely and accurate diagnostics.

Biosceptre International Limited is a biotechnology company based in Babraham, United Kingdom, focused on researching and developing innovative antibody products aimed at treating cancer. The company specializes in targeting the nf-P2X7 receptor and is engaged in the development of polyclonal antibodies for basal cell carcinoma and other skin cancers, as well as systemic therapies for various tumors. Additionally, Biosceptre is working on therapeutic anti-cancer vaccines and pioneering a multiple-targeted universal CAR T-cell therapy system. Established in 2013, the company aims to enhance the treatment options available to cancer patients globally through its diverse portfolio of next-generation cancer therapies, which include systemic antibodies, vaccines, and topical therapeutics.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.